ABUS
Arbutus Biopharma Corp
NASDAQ · Biotechnology
$3.84
+0.17 (+4.63%)
Open$3.84
Previous Close$3.67
Day High$3.90
Day Low$3.67
52W High$5.10
52W Low$2.71
Volume—
Avg Volume1.80M
Market Cap738.52M
P/E Ratio—
EPS$-0.22
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,234.6% upside
Current
$3.84
$3.84
Target
$51.25
$51.25
$34.47
$51.25 avg
$59.24
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 6.39M | 7.74M | 154.87M |
| Net Income | -72,448,457 | -79,034,680 | -18,750,475 |
| Profit Margin | -1,133.0% | -1,076.4% | -12.1% |
| EBITDA | -77,641,206 | -89,405,025 | -25,565,027 |
| Free Cash Flow | — | — | -20,118,850 |
| Rev Growth | -17.5% | -17.5% | +4.7% |
| Debt/Equity | — | — | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |